Eleven Biotherapeutics (EBIO) looks too good to be true. The nano-cap ($48.7 million) is the first red flag to notice. Its sharp rise from $0.25 in April to an intraday high of $8.00 in June on abnormal volume is another thing worth noting. Drastic price drops on over 15 million shares happen as often as the stock moving higher on that same, massive volume.EBIO struck a licensing deal with Hoffmann-La Roche for developing and commercializing its EBI-031 drug. The drug treats diabetic macular edema.EBIO is effectively up on a $7.5 million upfront payment. Future milestone payments would push the total to $262.5 million.This biotech is a dream coming true holding. Any time from this point forward, Roche could buy-out the company for $265 million, per the 8-K filing on June 10.EBIO suits speculators. La Roche stock suits value investors.More biotech ideas: 1.Proof that Valeant’s Recovery Depends on Salix Pharmaceuticals2.Valeant Pharmaceuticals Gets Cash Injection3.Galena is Worthless